This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (7)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Immunologic Disorders  • Multiple Sclerosis/ Demyelinating Disease  • Neuropathology  • Neurology, Other  • Alert me on articles by topic

Lars Bö, MD, PhD; Jeroen J. G. Geurts, PhD; Paul van der Valk, MD, PhD; Chris Polman, MD, PhD; Frederik Barkhof, MD, PhD

Arch Neurol. 2007;64(1):76-80.

Background  Histopathologic studies have shown that subpial cortical demyelination is extensive in chronic multiple sclerosis (MS).

Objective  To study whether subpial cortical demyelination in MS is associated with focal or diffuse white matter (WM) pathologic features on magnetic resonance imaging (MR imaging).

Design  Comparison of postmortem MR imaging findings with histopathologic findings.

Setting  Brain donations from a general community.

Patients  Three patients with MS with extensive cortical demyelination and 3 patients with minor cortical demyelination were selected from an MS autopsy data set. The postmortem MR imaging and histopathologic data of the patients were compared.

Main Outcome Measures  Two observers blinded to the results of each other assessed the presence, extent, and distribution of focal and diffuse pathologic changes in WM by MR imaging and by histopathology.

Results  Extensive subpial demyelination was not associated with a significant increase in the area of focal and diffuse WM pathologic changes as assessed by Luxol fast blue histochemistry or by MR imaging or with the presence or extent of juxtacortical abnormalities on MR imaging.

Conclusions  The lack of association of MS gray matter demyelination with diffuse or focal WM changes indicates that gray matter demyelination in MS occurs largely independent of WM pathologic changes. The extent or distribution of WM abnormalities cannot be used to identify extensive cortical demyelination in the clinical setting.

Author Affiliations: Departments of Pathology (Drs Bö and van der Valk), Radiology (Drs Geurts and Barkhof), and Neurology (Dr Polman), MS Center Amsterdam, VU University Medical Center, Amsterdam, the Netherlands; and National Competence Center for Multiple Sclerosis, Department of Neurology, Haukeland University Hospital, University of Bergen, Bergen, Norway (Dr Bö).

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Can imaging techniques measure neuroprotection and remyelination in multiple sclerosis?
Zivadinov
Neurology 2007;68:S72-S82.
ABSTRACT | FULL TEXT